
2012...2015. T-Cell Lymphomas: We are illuminating the darkest of tunnels Wednesday, April 29, 2015, Royal Hotel Carlton, Bologna, Italy

Mogamulizumab inside the T-cell family:

Mogamulizumab for PTCL

Kensei Tobinai, MD, PhD National Cancer Center Hospital, Tokyo, Japan

CCR4 Expression and Prognosis in T/NK-Cell Malignancies



0

Ω

Ishida T, et al.: Clin Cancer Res 2004;10:5494

Ohshima K, et al.: Int J Oncol 2004;25:605 modified


800

1200

Davs


400

CC Chemokine Receptor 4 (CCR4) & Mogamulizumab




POTELLIGENT® TECHNOLOGY

Defucosylation from the oligosaccharides on the Fc domain



Niwa R, et al.: Cancer Res 2004;64:2127



Japanese Phase II Study of Mogamulizumab

in Patients with Relapsed PTCL and CTCL

Ogura M, Ishida T, Tobinai K, Tsukasaki K, Akinaga S, Ueda R, et al.: KW-0761 Study Group in Japan


J Clin Oncol 2014;32:1157-63


Phase II Study of Mogamulizumab for PTCL/CTCL: Key Eligibility Criteria

- *CCR4-positive PTCL or CTCL
- Relapsed after the last chemotherapy by which objective response was obtained
- ECOG PS: 0 2
- Age \geq 20 years
- Normal function of the major organs
- No prior allogeneic SCT
- Negative for HBV surface antigen and HCV antibody

*Subtypes were confirmed by the Central Pathology Review *Ogura M, Tobinai K, et al.: J Clin Oncol 2014;32:1157-63*

Phase II Study of Mogamulizumab for PTCL/CTCL: Design





Phase II Study of Mogamulizumab for PTCL/CTCL: **Patient Demographics (n=37*)**


Characteristic		N	%				
	Madian (ranga)						
Age, years	Median (range)	64 (33	5-80)				
Sex	Male	23	62				
	Female	14	38				
PS	0	24	65				
	1	12	32				
	2	1	3				
Prior Chemotherapy	Median (range)	2 (1	-6)				
Lymphoma Subtype							
	PTCL	29	78				
	PTCL-NOS	16	43				
	AITL	12	32				
	ALCL-ALK (-)	1	3				
	CTCL	8	22				
	MF	7	19				
	C-ALCL	1	3				

Phase II Study of Mogamulizumab for PTCL/CTCL: Efficacy Assessment* (n=37)

Lymphoma Subtype	N		Best R	esponse	- ORR (%)	[95% CI]	
	IN	CR	PR	SD	PD	- UNN (<i>7</i> 0)	[95% CI]
PTCL	29	5	5	9	10	34%	[18 - 54]
PTCL-NOS	16	1	2	6	7	19%	
AITL	12	3	3	3	3	50%	
ALCL ALK (-)	1	1 (CRu)	0	0	0	100%	
CTCL	8	0	3	4	1	38%	[9 - 76]
MF	7	0	2	4	1	29%	
C-ALCL ⁺	1	0	1	0	0	100%	
Total	37	5	8	13	11	35%	[20 - 53]

*Evaluated by Efficacy Assessment Committee / †Cutaneous ALCL


CCR4 Expression Levels Determined by IHC



There was no correlation between ORR and CCR4 expression level.

	Tumor cells		
CCR4 nega	< 10%		
CCR4 positive	1+	10≤ <25%	
	2+	25≤ <50%	
	3+		

Phase II Study of Mogamulizumab for PTCL/CTCL: **Progression-free Survival (PFS)**




Mogamulizumab for PTCL/CTCL: Adverse Events* (n=37)

	Patients affected, N			I, N		Patients affected, N			Ν
Non-Hematologic	Gra	ade	- All Grades		Hematologic	Grade		- All Grades	
AEs	3	4			AEs	3 4 All Gra		lues	
Pyrexia	0	0	11	30%	Lymphopenia	16	11	30	81%
Rash	2	0	10	27%	Leukocytopenia	3	2	16	43%
ALP increased	1	0	8	22%	Neutropenia 4 3		3	14	38%
ALT increased	1	0	8	22%	Thrombocytopenia	0	1	14	38%
Phosphorus decreased	1	0	6	16%	Anemia	1	1	5	14%
Hypokalemia	1	0	2	5%	Febrile Neutropenia	1	0	1	3%
Secondary malignancy *	0	1	1	3%					
Herpes esophagitis	1	0	1	3%	*Possibly/probably/definitely drug-related				d
Infection	1	0	1	3%					
Oral candidiasis	1	0	1	3%					
Pneumonia	1	0	1	3%					
Polymyositis	1	0	1	3%	In another phase II study for ATL, skin				
Skin disorders	4	0	19	51%	disorders were observed in 67% (18/27).				
Acute Infusion reaction	0	0	9	24%					
	*D:tf	co lorgo	D coll lun	anhama					

*Diffuse large B-cell lymphoma

Phase II Study of Mogamulizumab for PTCL/CTCL: An Ancillary Study (Tobinai K, et al.: T-Cell Lymphoma Forum, 2015)



Phase II Study of Mogamulizumab for PTCL/CTCL

- 35% of ORR (13/37; 95% CI, 20 53%) met the primary endpoint defined as the best ORR (Threshold; 5%, Expected; 25%).
- Median PFS was 3.0 months.
- Median duration of response (DOR) and time to response (TTR) for PTCL responders (n=10) were 6.4 and 1.9 months, respectively.
- Most common AEs were skin disorders, acute infusion reaction, pyrexia and hematologic toxicities.

Mogamulizumab is an effective agent with acceptable toxicities for relapsed PTCL & CTCL, leading to its approval in Japan in 2014.

Ogura M, Tobinai K, et al: J Clin Oncol 2014;32:1157-63 / Tobinai K, et al.: TCLF 2015

European Phase II Study of Mogamulizumab in Previously Treated PTCL


Best OR by Subtype	No of subjects	CR/PR n (%)	SD n (%)	>SD n (%)
PTCL-NOS	15	2* (13%)	6 (40%)	8 (53%)
AITL	12	2 (17%)	3 (25%)	5 (42%)
TMF	3	0	1 (33%)	1 (33%)
ALCL-ALK neg	4	0	2 (50%)	2 (50%)
ALCL-ALK pos	1	0	0	0
Evaluable Subjects	35	4 (11%)	12 (34%)	16 (46%)

The median PFS was 2.1 months; similar results to the Japanese phase II study.

The differences in ORRs between 2 studies (35% vs 11%) are partly due to the differences in patient population, including relapsed pts (100% vs 49%) and PS 2 (3% vs 39%).

Zinzani PL, et al.: Blood, Dec 2014;124:1763 (ASH 2014)

Worldwide Development Status of Mogamulizumab (as of April 2015)



Courtesy of Kyowa-Kirin

Acknowledgments

Investigators

Katsuya Fujimoto Kenichi Ishizawa **Kiyohiko Hatake** Kiyoshi Ando Michinori Ogura Kazuhito Yamamoto Takashi Ishida Motoko Yamaguchi Masafumi Taniwaki Mitsune Tanimoto Toshihiro Miyamoto Naokuni Uike Kunihiro Tsukasaki Atae Utsunomiya

Flow Cytometry

Junichi Tsukada Kouichi Nakata

Immunohistochemistry

Shigeo Nakamura Hiroshi Inagaki Kouichi Ohshima

Safety Review Committee

Kuniaki Itoh Noriko Usui Hirokazu Nagai

Efficacy Review Committee

Junji Suzumiya Takashi Terauchi Ukihide Tateishi

Dermatologist

Tetsuo Nagatani Akimichi Morita

Expert Oncologist

Kazuo Tamura Ryuzo Ueda

- Study Chairman Masao Tomonaga
- Kyowa Hakko Kirin

Shiro Akinaga

Sponsored by KYOWA KIRIN

We would like to thank the patients who participated in this study and their families, as well as CRCs, study coordinators, and operation staffs.